pharma · Recurrent Pericarditis · Sjögren’s Disease · KNSA
Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals is a pharma organization headquartered in Lexington, USA. It trades on NYSE under ticker KNSA. Primary therapeutic focus areas include Recurrent Pericarditis, Sjögren’s Disease, Well-Controlled Re
100 Hayden Ave, Lexington, Massachusetts 02421, US HQ
2015 Founded
381 Employees
Public company Type
KNSA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 100 Hayden Ave, Lexington, Massachusetts 02421, US
- Founded
- 2015
- Employees
- 381
- Programs
- 14
- Drugs
- 7
- Patents
- 9
Mavrilimumab
Phase 2 · small molecule · COVID-19
Mavrilimumab for COVID-19 is a Phase 2 program (small_molecule) at Kiniksa Pharmaceuticals International, plc with 3 ClinicalTrials.gov record(s).
Internal code HM20019145
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kiniksa Pharmaceuticals International, plc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- COVID-19
- Status
- completed
- Trials
- 3